Benchling

Market position

Benchling positions itself as a leading cloud platform for modern life sciences R&D, contrasting its offering with paper, spreadsheets and legacy scientific software [5]. It reports adoption by more than 1,300 organizations and a community of roughly 200,000 scientists, and states that more than half of the world's top 50 biopharma companies use the product [0][2][3]. Earlier disclosures cited 22 of the 50 largest global biopharma companies and over 600 corporate customers as of late 2021 [7].

Benchling emphasizes software built around actual scientist workflows and user experience rather than legacy informatics systems, a single platform spanning discovery through process development, a configurable unified data model that connects wet-lab and computational work, codeless configuration, open APIs and integrations, enterprise security and compliance tooling, and AI grounded in customers' own scientific data. The company also notes that nearly half its team comes from R&D backgrounds [0][2][3][5].

Technology

The platform is delivered as multi-tenant cloud software combining a collaborative electronic lab notebook, a configurable unified scientific data model, workflow automation and analytics, and molecular biology/sequence tools (restriction digest, primer creation, alignments, version history, GenBank/FASTA/SBOL export) [0][4]. Integration and extensibility are provided via REST APIs, an events system, prebuilt integrations, custom apps and an interface designer, and Benchling Connect for instrument and system data unification. Security and compliance features include access controls, audit trails, validated workflows, SOC 2 Type II certification and a Validated Cloud option for GxP-oriented use [3]. AI capabilities are embedded in the notebook for data analysis and report writing and in the company's "AI Scientist" loop linking predictive models with lab execution [0].

Go-to-market

Go-to-market combines direct enterprise sales (demo requests, contact sales) with a free academic community edition that seeds adoption among students and researchers, plus a partner/developer ecosystem of APIs, out-of-the-box integrations and custom apps, a user community with events and workshops, and training and certification programs [0][3][7]. The company has expanded geographically to serve major biotech hubs, opening an EMEA headquarters in Zurich and building a European team [6][7].

Scientific R&D teams in biopharma, biotechnology, agriculture, food, materials, industrial fuels, consumer packaged goods and life science diagnostics, ranging from academic labs and startups to large global enterprises; named customers include Gilead Sciences, Sanofi, Regeneron Pharmaceuticals, Corteva Agriscience, Sana Biotechnology, Editas, Cutiss AG, Selexis SA and Syngenta [5][6][7].

Geography

Headquartered in San Francisco, California [5][6][7]. Benchling opened an EMEA headquarters in Zurich, Switzerland, and within a year of entering the EMEA market reported over 90 European customers and a European team of more than 60 people [6][7]. Customers are described as global [6].

History

Founded in 2012 [5][6]. By October 2016 the company had raised over $13 million in total and served more than 40,000 scientists with an integrated notebook, LIMS and molecular biology platform [5]. In January 2021 it reported doubling ARR for the fourth consecutive year and opened an EMEA headquarters in Zurich; in April 2021 it raised a $200 million Series E led by Sequoia Capital Global Equities [6]. Later in 2021 it added support for Early Development and RNA therapeutics, hired Salesforce executive Lindsey Irvine as Chief Marketing Officer, and in November 2021 raised a $100 million Series F at a $6.1 billion valuation [7]. More recently the company has centered its positioning on AI-native R&D, including releases announced at its Benchtalk 2025 event [2].

Risks & controversies

No controversies, litigation or negative events are described in the available sources. Investor-relevant caveats include that most growth, revenue and customer figures are company-reported and, in several cases, several years old; the November 2021 press release itself carries a forward-looking-statements disclaimer noting risks such as the ability to sustain growth rates and sales and marketing execution [7].